Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.45 USD
+0.12 (9.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.43 -0.02 (-1.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Clearside Biomedical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 1 | 30 | 8 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 8 | 1 | 30 | 8 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 33 | 31 | 30 | 26 | 32 |
Income After Depreciation & Amortization | -25 | -30 | -1 | -18 | -30 |
Non-Operating Income | -8 | 1 | 1 | 0 | 0 |
Interest Expense | 0 | 3 | 0 | 0 | 0 |
Pretax Income | -32 | -33 | 0 | -18 | -31 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -32 | -33 | 0 | -18 | -31 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -32 | -33 | 0 | -18 | -31 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -30 | 0 | -18 | -30 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -25 | -30 | -1 | -18 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 61.81 | 60.21 | 59.91 | 46.51 | 38.17 |
Diluted EPS Before Non-Recurring Items | -0.53 | -0.55 | 0.01 | -0.39 | -0.81 |
Diluted Net EPS (GAAP) | -0.53 | -0.55 | 0.01 | -0.39 | -0.81 |
Fiscal Year end for Clearside Biomedical, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.09 | 0.23 | 6.34 | 0.86 | 1.02 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.14 | 0.21 |
Gross Profit | 0.09 | 0.23 | 6.34 | 0.72 | 0.81 |
SG&A, R&D, and Dept/Amort Expenses | 7.68 | 8.44 | 9.26 | 7.77 | 8.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.59 | -8.21 | -2.92 | -7.05 | -7.27 |
Non-Operating Income | 0.00 | -3.55 | -4.08 | -2.21 | -1.84 |
Interest Expense | 0.00 | 0.00 | -2.17 | 0.00 | 0.00 |
Pretax Income | -7.59 | -11.76 | -4.83 | -9.27 | -9.11 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.59 | -11.76 | -4.83 | -9.27 | -9.11 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.59 | -11.76 | -4.83 | -9.27 | -9.11 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 74.73 | 69.85 | 62.40 | 61.98 | 61.66 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.17 | -0.08 | -0.15 | -0.15 |
Diluted Net EPS (GAAP) | -0.10 | -0.17 | -0.08 | -0.15 | -0.15 |